Unraveling the Potential of FAM219A as a Drug Target or Biomarker

Target Name: FAM219A

NCBI ID: G203259

FAM219A

Unraveling the Potential of FAM219A as a Drug Target or Biomarker

FAM219A, a 21-kDa protein located in the N-end region of the human protein kinase CKL2-associated protein 2 (CKL2AP2), has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure, which consists of a N-end region containing a farnesylated cysteine residue, a single transmembrane segment, and an N-end insertion loop, has piqued the interest of researchers due to its potential to modulate various cellular processes.

Potential Drug Target

FAM219A has been shown to play a critical role in cell signaling pathways, particularly in the regulation of protein kinase activity. Its N-end region, which is rich in cysteine residues, has been shown to have a unique structural flexibility, allowing it to interact with various protein partners, including other proteins involved in cell signaling pathways, such as casein kinase 2 (CKL2), which is a key regulator of cell growth, development, and survival.

Furthermore, overexpression of FAM219A has been shown to increase the activity of several protein kinases, including CKL2, leading to increased cell proliferation and survival. This suggests that FAM219A may be a useful drug target for cancer and neurodegenerative diseases.

Potential Biomarker

FAM219A has also been detected as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and its ability to interact with other proteins involved in cell signaling pathways make it an attractive candidate for diagnostic applications.

FAM219A has been shown to be expressed in various tissues and cells, including cancer cells, neurodegenerative disease tissues, and autoimmune disease samples. Additionally, its expression has been shown to be associated with several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Furthermore, studies have shown that FAM219A has been associated with several proteins involved in disease progression, including histone modifications, protein-protein interactions, and signaling pathways. This suggests that FAM219A may be a useful biomarker for disease diagnosis and prognosis.

Conclusion

In conclusion, FAM219A is a unique and promising protein that has potential as a drug target or biomarker. Its unique structure and its ability to interact with other proteins involved in cell signaling pathways make it an attractive candidate for both drug development and disease diagnosis. Further research is needed to fully understand the role of FAM219A in cell signaling pathways and its potential as a drug target or biomarker.

Protein Name: Family With Sequence Similarity 219 Member A

The "FAM219A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM219A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets